Bank of America
ABUS icon

Bank of America’s Arbutus Biopharma ABUS Stock Holding History

Bank of America’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-504,800
Closed -$1.96M – 8206
2021
Q4 		$1.96M Sell
504,800
-717,200
-59% -$2.79M ﹤0.01% 4574
2021
Q3 		$5.24M Buy
1,222,000
+1,134,000
+1,289% +$3.78M ﹤0.01% 3518
2021
Q2 		$267K Buy
+88,000
New +$273K ﹤0.01% 5879
2015
Q3 		– Sell
-50,000
Closed -$593K – 7166
2015
Q2 		$593K Buy
+50,000
New +$761K ﹤0.01% 4568

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bank of America's ABUS Position: Q1 2026 in Review

Bank of America reduced its Arbutus Biopharma (ABUS) stake by 8.1% in Q1 2026, selling an estimated $652K and leaving 1,683,628 shares worth $7.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3160.

Bank of America first reported a position in ABUS in Q1 2014 and has held it in 49 quarters since. The position peaked at $8.82M in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Bank of America held 1,683,628 shares of Arbutus Biopharma worth $7.58M as of Q1 2026.
  • Bank of America sold 149,076 Arbutus Biopharma shares in Q1 2026, an estimated $652K.
  • Arbutus Biopharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3160 holding.
  • Bank of America first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 49 quarters since.
  • Bank of America's Arbutus Biopharma position peaked at $8.82M in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.